Wall Street analysts forecast that AxoGen, Inc (NASDAQ:AXGN) will post sales of $28.10 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for AxoGen’s earnings. AxoGen posted sales of $22.66 million during the same quarter last year, which suggests a positive year over year growth rate of 24%. The firm is scheduled to report its next earnings report on Monday, November 4th.
On average, analysts expect that AxoGen will report full-year sales of $107.30 million for the current year, with estimates ranging from $107.00 million to $107.80 million. For the next financial year, analysts anticipate that the firm will post sales of $139.83 million, with estimates ranging from $136.60 million to $146.00 million. Zacks’ sales calculations are an average based on a survey of research firms that that provide coverage for AxoGen.
AxoGen (NASDAQ:AXGN) last issued its earnings results on Tuesday, August 6th. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.09. AxoGen had a negative net margin of 26.91% and a negative return on equity of 16.73%. The company had revenue of $26.70 million for the quarter, compared to analysts’ expectations of $26.77 million. During the same period in the prior year, the business earned ($0.09) EPS. The firm’s quarterly revenue was up 29.7% on a year-over-year basis.
AxoGen stock traded down $0.76 during midday trading on Wednesday, hitting $15.96. 324,345 shares of the company’s stock were exchanged, compared to its average volume of 874,150. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.87 and a current ratio of 8.70. AxoGen has a 12 month low of $11.82 and a 12 month high of $46.25. The firm has a 50-day moving average of $17.52 and a two-hundred day moving average of $19.73. The company has a market cap of $651.63 million, a PE ratio of -29.56 and a beta of 0.18.
In other news, Director Quentin S. Blackford purchased 15,535 shares of the stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $14.01 per share, for a total transaction of $217,645.35. Following the acquisition, the director now owns 25,098 shares of the company’s stock, valued at $351,622.98. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Karen L. Zaderej purchased 75,000 shares of the stock in a transaction dated Friday, August 9th. The stock was purchased at an average price of $13.50 per share, for a total transaction of $1,012,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 593,280 shares in the company, valued at approximately $8,009,280. The disclosure for this purchase can be found here. Insiders bought a total of 102,535 shares of company stock worth $1,434,422 over the last 90 days. Company insiders own 6.77% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of AxoGen by 8.5% in the 2nd quarter. BlackRock Inc. now owns 2,674,036 shares of the medical equipment provider’s stock valued at $52,947,000 after buying an additional 208,805 shares in the last quarter. Vanguard Group Inc. boosted its stake in AxoGen by 5.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,768,572 shares of the medical equipment provider’s stock worth $35,018,000 after purchasing an additional 93,873 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in AxoGen by 2.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,104,983 shares of the medical equipment provider’s stock worth $21,878,000 after purchasing an additional 27,616 shares in the last quarter. Baillie Gifford & Co. boosted its stake in AxoGen by 54.0% in the 1st quarter. Baillie Gifford & Co. now owns 980,700 shares of the medical equipment provider’s stock worth $20,654,000 after purchasing an additional 343,900 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in AxoGen by 25.8% in the 2nd quarter. Bank of America Corp DE now owns 763,705 shares of the medical equipment provider’s stock worth $15,122,000 after purchasing an additional 156,476 shares in the last quarter. Institutional investors and hedge funds own 87.67% of the company’s stock.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.